ISLAND PHARMACEUTICALS LIMITED (ILA)
Share Price Analysis and Chart

09/07/2026

-1

No Rating

-4.55%

Research as a Service (RaaS) believes Island Pharmaceuticals has enhanced the commercial potential of its Galidesivir drug. This follows the securing of approvals for compassionate use during the Bundibugyo Ebola outbreak in Africa.

The analyst expects the program to generate prospective human efficacy, safety and virology data across filoviruses, complementing the company's Marburg virus development under the FDA's Animal Rule pathway.

The Uganda Government is fully funding the program with support from the World Health Organisation, providing a non-dilutive opportunity to expand Galidesivir's clinical dataset, the analyst explains.

Research as a Service raises its probability of success to 65% from 60% and increases its risk-adjusted valuation to $1.60 a share from $1.24.

Research as a Service research doesn't carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

FORECAST
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.77 cents.
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -4.70 cents.